Dell

The new hardware expands Garvan's current system so that it can better support large-scale whole-genome and single-cell sequencing initiatives.

Dell Technologies Capital, newly out of stealth, invested in Edico Genome because it believes whole-genome sequencing is almost ready to take off on a wide scale.

Sequencing IT developer Edico said it will use the funding to build out its Dragen bioinformatics processor and step up marketing efforts.

The combined product includes Edico’s Dragen bioinformatics processor integrated into a Dell server, as well as Dell EMC’s Isilon storage.

Dell plans to begin allowing clinical customers to store genomic datasets alongside patients' medical imaging data this spring.

The High Performance Computing Solution for Genomics is a pre-configured computer hardware platform specifically designed for clinical genomic analysis.

The funding will be used to optimize a high-performance computing infrastructure for the analysis and storage of genetic data.

NEW YORK (GenomeWeb) – Dell, the Translational Genomics Research Institute, and Terascala will provide the National Cancer Institute with a high performance computing system, programming applications, expertise, and software to support genomics research projects, TGen said today.

This week, Terascala said that it has released a new version of the Intelligent Storage Bridge (ISB), a high-performance data-movement appliance which the company first introduced last fall to help its customers, especially those in the genomics arena, move large quantities of da

DNAnexus has launched a developer program that offers bioinformaticians and software engineers the technical and support resources needed to create and integrate data analysis applications on its platform.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.